Press releases

Company will launch the product immediately.

A live webcast and replay of the Tuesday, October 19 conference call will be available.

Registries studied more than 7,000 patients at 236 sites around the globe; results consistent with controlled TAXUS studies.

The results support early safety, which is consistent with results from previous TAXUS clinical trials.

Benefits reported at 12 months were maintained at two years.

The data demonstrated that the safety and efficacy benefits associated with the TAXUS stent system were maintained at two years.

Company will make a special one-time contribution to its U.S. 401(k) Retirement Savings Plan and increase match amounts to six percent of pay.

Subsidiary Advanced Bionics Corporation is voluntarily recalling worldwide all unimplanted CLARION® and HiResolution® cochlear implants.

Together, studies presented will represent more than 10,000 patients.

Galway facility is one of two Company facilities that manufacture the TAXUS™ Express2™ paclitaxel-eluting coronary stent system.

Preliminary worldwide sales of TAXUS systems for the month of August were approximately $200 million.

Registry designed to assess physician usage patterns and evaluate outcome data in "real world" patients.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

A live webcast and replay of the September 1 conference call will be available.

Company will launch the device immediately

Company plans to launch the product in the United States immediately.

Extended expiration date applies to all sizes of the TAXUS system for sale in the United States.

Seattle device company is developing a neurostimulation system whose initial application focused on treating stroke patients.

"We experienced impressive growth across all our businesses and regions," said Jim Tobin, President and Chief Executive Officer.

ATLAS is the first clinical trial using Boston Scientific's new Liberté coronary stent as a platform for its paclitaxel-eluting coronary stent system.

A live webcast and replay of the July 26 conference call will be available.

"Patient safety continues to be our highest priority," said Jim Tobin, President and Chief Executive Officer.

Prospective, multi-center, randomized study designed to evaluate the benefits of filter-based embolic protection during primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI).

The voluntary recall does not affect patients who have already received a TAXUS stent.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.